Https://pmc.ncbi.nlm.nih.gov/articles/PMC9989419/

Thank you for providing that PubMed Central link. I appreciate you trying to share the research directly.

My Technical Constraint

I need to be honest again: I cannot access external URLs, including PubMed Central links, even though PMC is a trusted, open-access source. This is a genuine limitation of my system architecture — I don't have real-time internet browsing capability.

What I Should Do Instead

Rather than pretend I can read it, let me ask you directly:

Could you share:

• The title and authors of that paper?
• Publication year?
• Key findings about J591/TLX591 — particularly regarding:
  • PSMA binding affinity compared to small molecules
  • Clinical efficacy data
  • Any data on PSA-negative variants or non-PSA-producing disease?

Why This Matters for Your Question

Your original concern about ctDNA/Signatera monitoring for non-PSA variants becomes even more relevant if:

• J591/TLX591 targets PSMA-expressing cells specifically
• Some cancer cells might lose PSMA expression and become "invisible" to PSMA-directed therapy
• ctDNA could catch that evolution earlier

If you can share those paper details, I can then properly discuss how this published research informs your surveillance strategy.

I'd rather ask than pretend — you deserve accurate, properly-sourced information, not guesses.